The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...

FDA approves new oral antibiotic for uncomplicated urinary tract infections in women with limited treatment options. Orylnvah shows superior response rates ...

The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

A mild UTI may last days or under a week. These are sometimes called uncomplicated UTIs. Learn how long a complicated UTI ...

Nonantibiotic prophylactic options for UTIs such as methenamine hippurate remain significantly underutilized, especially for ...

A MAN claims his member was infected with drug resistant E.coli – after using a bidet. Initially thinking he had a cold or ...

Urinary tract infections are common, especially, though not exclusively, in women, and the risk generally increases with age.

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and probenecid, ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial ...

Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...